MAPT and Alzheimer disease: Increasing evidence suggests that increased expression of GSK‐3β is associated with synaptic dysfunction in AD (Facci & Skaper, 2006; Peineau et al., 2007), Tau and β‐amyloid protein aggregation (Llorens‐Marítin et al., 2014; Pérez et al., 2002), and neuroinflammation (Michelucci et al., 2009).